BlackRock
DAWN

BlackRock’s Day One Biopharmaceuticals DAWN Stock Holding History

BlackRock’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151M Sell
7,044,487
-1,793,087
-20% -$25.3M ﹤0.01% 1847
2025
Q4 		$82.4M Sell
8,837,574
-163,881
-2% -$1.37M ﹤0.01% 2229
2025
Q3 		$63.5M Sell
9,001,455
-828,976
-8% -$5.7M ﹤0.01% 2362
2025
Q2 		$63.9M Buy
9,830,431
+3,072,502
+45% +$21.1M ﹤0.01% 2316
2025
Q1 		$53.6M Buy
6,757,929
+602,092
+10% +$6.49M ﹤0.01% 2343
2024
Q4 		$78M Buy
6,155,837
+1,446,675
+31% +$20.1M ﹤0.01% 2218
2024
Q3 		$65.6M Buy
4,709,162
+175,720
+4% +$2.51M ﹤0.01% 2318
2024
Q2 		$62.5M Sell
4,533,442
-497,993
-10% -$7.29M ﹤0.01% 2286
2024
Q1 		$83.1M Sell
5,031,435
-94,636
-2% -$1.42M ﹤0.01% 2165
2023
Q4 		$74.8M Buy
5,126,071
+437,637
+9% +$5.31M ﹤0.01% 2256
2023
Q3 		$57.5M Buy
4,688,434
+1,123,701
+32% +$14.7M ﹤0.01% 2323
2023
Q2 		$42.6M Buy
3,564,733
+1,306,238
+58% +$17.1M ﹤0.01% 2585
2023
Q1 		$30.2M Sell
2,258,495
-176,773
-7% -$3.45M ﹤0.01% 2755
2022
Q4 		$52.4M Sell
2,435,268
-105,967
-4% -$2.17M ﹤0.01% 2433
2022
Q3 		$50.9M Buy
2,541,235
+578,511
+29% +$12.3M ﹤0.01% 2422
2022
Q2 		$35.1M Buy
1,962,724
+799,808
+69% +$8.26M ﹤0.01% 2732
2022
Q1 		$11.5M Buy
1,162,916
+410,797
+55% +$5.43M ﹤0.01% 3502
2021
Q4 		$12.7M Buy
752,119
+230,846
+44% +$4.74M ﹤0.01% 3526
2021
Q3 		$12.4M Buy
521,273
+516,901
+11,823% +$12.4M ﹤0.01% 3579
2021
Q2 		$99K Buy
+4,372
New +$91.2K ﹤0.01% 5051

Other funds holding DAWN

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock's DAWN Position: Q1 2026 in Review

BlackRock reduced its Day One Biopharmaceuticals (DAWN) stake by 20% in Q1 2026, selling an estimated $25.3M and leaving 7,044,487 shares worth $151M. The position accounts for ﹤0.01% of the portfolio, ranked #1847.

BlackRock first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • BlackRock held 7,044,487 shares of Day One Biopharmaceuticals worth $151M as of Q1 2026.
  • BlackRock sold 1,793,087 Day One Biopharmaceuticals shares in Q1 2026, an estimated $25.3M.
  • Day One Biopharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #1847 holding.
  • BlackRock first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.